Skip to main content
. Author manuscript; available in PMC: 2014 May 10.
Published in final edited form as: Curr Pharm Des. 2012;18(9):1173–1185. doi: 10.2174/138161212799436368

TABLE 1.

Shown are improvements in JNK1 and JNK2 protein-inhibitor structural models using Ewald refinement. The R/Rfree statistics for the deposited PDB structures are shown as originally reported and after recalculation using the Force Field X program. After Ewald refinement, the final structural models improved the mean Rfree value relative to the recalculated Rfree by 1.4% on average. In addition, the mean MolProbity score was improved from the 51rst percentile to the 97th percentile (see the text for a description of the MolProbity structure validation tool).

PDB / Ligand Original Refinements
Ewald Refinements
Res (Å) R / Rfree MolProbity
Recalculated R / Rfree Final R / Rfree MolProbity
RMSD (Å)
Score % Score %
3O17 / Apo 3.0 26.3 / 30.8 3.9 17 25.5 / 30.6 22.9 / 27.9 2.3 97 0.38
3O2M / 46A 2.7 23.3 / 26.6 3.3 30 22.8 / 26.4 19.7 / 24.9 2.3 94 0.25
3NEW / 3NE 2.5 21.9 / 30.6 3.0 42 22.0 / 30.6 21.6 / 29.2 1.6 99 0.40
3E7O / 35F 2.1 21.9 / 25.0 2.1 77 21.7 / 24.6 18.4 / 23.0 1.6 97 0.39
3NPC / B96 2.4 21.4 / 25.4 2.1 88 21.0 / 24.7 18.8 / 25.0 1.7 98 0.16

Mean 2.5 23.0 / 27.7 2.9 51 22.7 / 27.4 20.3 / 26.0 1.9 97 0.31